fd

Home/Fatéma Dodat

About Fatéma Dodat

Fatéma Dodat est candidat doctorale en Sciences Pharmaceutiques à la Faculté de Pharmacie et à l'Institut de Recherche en Immunologie et en Cancérologie (IRIC) de l'Université de Montréal. Avec une double formation en sciences pharmaceutiques et en biologie moléculaire, je suis passionnée par la recherche et la compréhension des avancées, défis et controverses scientifiques. Par ailleurs, j’aime rendre la science accessible et intéressante au plus grand nombre. C’est une des raisons pour lesquelles j’ai créé cette plateforme de vulgarisation scientifique qui publient des articles d’étudiants aux cycles supérieurs et jeunes chercheurs :https://fr.point-science.com/ -- Fatéma Dodat is a PhD candidate in Pharmaceutical Sciences at Faculté de Pharmacie and Institut de Recherche en Immunologie et en Cancérologie (IRIC) of Université de Montréal. With a double background in pharmaceutical sciences and molecular biology, I am passionate about research and understanding scientific advances, challenges and controversies. Furthermore, I like to make science accessible and interesting to as many people as possible. That is one of the reasons why I created this popular science platform that published papers of graduate students and young researchers : https://en.point-science.com/
11 09, 2020

Towards a massive screening of COVID-19? The EasyCOV saliva test

By |2021-02-12T00:21:49-05:00September 11th, 2020|Vaccines and Therapeutics|0 Comments

"Test, test, test" has been the leitmotif of the World Health Organization (WHO) since the start of the pandemic. However, mass screening requires a rapid, simple and effective detection test. To answer this question, french researchers carried out a real race against the clock in the laboratory in order to produce and market this test in record time. This one, called EasyCOV1, requires a saliva sample and provides the results in 1 hour. Back on this test and its mode of action.

11 09, 2020

What is this promising COVID-19 vaccine developed by Moderna?

By |2021-02-12T13:52:44-05:00September 11th, 2020|Vaccines and Therapeutics|0 Comments

In mid-May, the American company Moderna announced that the vaccine developed against Covid-19 had triggered an immune response in 8 patients. These patients secreted antibodies in an amount comparable to those seen in infected patients and recovered from the coronavirus. Among the panoply of vaccine strategies currently being tested, to which category does Moderna belong?

11 09, 2020

The lockdown related to COVID-19 severely affected early-career investigators and clinical trials

By |2021-02-12T00:22:46-05:00September 11th, 2020|Clinical Trials|0 Comments

The research sectors particularly impacted by the pandemic are beginning to be identified. David Knapp, Principal Investigator at IRIC, in collaboration with David G. Kent (University of York) and Nagarajan Kannan (Mayo Clinic), highlight the consequences of the health crisis on early-career investigators and clinical trials.

Go to Top